8-K: Sutro Biopharma Receives NASDAQ Delisting Warning Over Minimum Bid Price

Sutro Biopharma, Inc. has received a notice from NASDAQ indicating non-compliance with the $1.00 minimum bid price requirement, initiating a 180-day period to regain compliance.

Summary

• Sutro Biopharma, Inc. (the "Company") received a written notice from The NASDAQ Stock Market, LLC on June 20, 2025.
• The notice indicates non-compliance with NASDAQ Listing Rule 5450(a)(1), which requires a minimum bid price of $1.00 per share for continued listing on The NASDAQ Global Market.
• The Company has 180 calendar days, until December 17, 2025, to regain compliance with the minimum bid price requirement.
• To regain compliance, the closing bid price of the Company's common stock must meet or exceed $1.00 per share for a minimum of ten consecutive business days during this 180-day period.
• If compliance is not met by December 17, 2025, the Company may be afforded a second 180-calendar day period to regain compliance if it elects to transfer to The NASDAQ Capital Market and meets other initial listing standards.
• The Company intends to monitor the closing bid price of its common stock and, if necessary, plans to implement a reverse stock split prior to December 17, 2025, to cure the deficiency.

Sentiment

Score: 3

Explanation: The document conveys negative news regarding the company's stock price non-compliance with NASDAQ listing rules, indicating potential delisting risk and the need for remedial actions like a reverse stock split, which are generally viewed unfavorably by investors.

Negatives

• Receipt of a formal notice of non-compliance with NASDAQ's $1.00 minimum bid price requirement.
• Risk of delisting from The NASDAQ Global Market if compliance is not regained within the specified period.
• Potential necessity of a reverse stock split, which can sometimes be perceived negatively by investors and may not guarantee long-term price stability.

Risks

• Failure to regain compliance with NASDAQ's minimum bid price requirement, leading to potential delisting of the Company's common stock.
• The need to implement a reverse stock split, which could impact shareholder perception, stock liquidity, and potentially lead to further price declines.
• Transfer to The NASDAQ Capital Market, which might be perceived as a downgrade in listing status.

Future Outlook

Sutro Biopharma intends to actively monitor the closing bid price of its common stock and plans to implement a reverse stock split if necessary, prior to the December 17, 2025 deadline, to regain compliance with NASDAQ's minimum bid price requirement. The Company may also seek to transfer to The NASDAQ Capital Market for an extended compliance period if initial compliance is not met.

Management Comments

• "The Company intends to monitor the closing bid price of its common stock and, if necessary, plans to implement a reverse stock split prior to December 17, 2025."

Industry Context

Companies in the biotechnology and pharmaceutical sectors, particularly those in early or mid-stages of development, often face challenges in maintaining stock prices above exchange minimums due to high R&D costs, long development cycles, and reliance on clinical trial outcomes. Non-compliance with listing standards, such as minimum bid price, is a common issue for smaller cap companies in this industry, often leading to reverse stock splits as a remedial measure to avoid delisting.

Stakeholder Impact

• Shareholders: Face potential for increased stock price volatility, reduced liquidity if delisted, and the impact of a reverse stock split which can reduce the number of shares held while increasing the per-share price, potentially affecting investor confidence.

Next Steps

• Monitor the closing bid price of the common stock to ensure it meets or exceeds $1.00 for ten consecutive business days.
• Implement a reverse stock split if necessary, prior to December 17, 2025, to cure the minimum bid price deficiency.
• Potentially elect to transfer to The NASDAQ Capital Market to take advantage of an additional 180-day compliance period if initial compliance is not met.
• Notify NASDAQ of its intent to cure the minimum bid price deficiency.
• Appeal NASDAQ Staff's delisting determination to a NASDAQ Listing Qualifications Panel and request a hearing, if compliance is not regained within allotted periods.

Key Dates

Recommendation

Keywords

Sutro Biopharma, STRO, NASDAQ, delisting notice, minimum bid price, stock compliance, reverse stock split, biopharma, biotechnology